Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Medication
|
| gptkbp:activeDuring |
Minocycline
|
| gptkbp:administrativeDivision |
Once every 3 months
Intra-pocket_placement |
| gptkbp:availability |
Prescription only
|
| gptkbp:clinicalTrials |
gptkb:American_Academy_of_Periodontology
gptkb:European_Federation_of_Periodontology Phase III Local delivery therapy Study_of_Arestin_in_periodontal_disease |
| gptkbp:contraindication |
Diarrhea
Dizziness Pregnancy Vomiting Skin rash Lactation Hypersensitivity to minocycline Oral mucosal ulceration |
| gptkbp:date |
2001-06-29
|
| gptkbp:dosageForm |
Powder
|
| gptkbp:drugInterdiction |
Anticoagulants
Oral contraceptives Other antibiotics Localized delivery Tetracycline antibiotics |
| gptkbp:formulation |
Microspheres
Sustained-release |
| gptkbp:hasPopulation |
Adults
|
| gptkbp:historical_analysis |
Arestin_in_combination_with_scaling
Arestin_vs._placebo Efficacy_of_Arestin_in_chronic_periodontitis Long-term_effects_of_Arestin Patient_satisfaction_with_Arestin_treatment |
| https://www.w3.org/2000/01/rdf-schema#label |
Arestin
|
| gptkbp:impact |
Up to 12 months
Patient-reported outcomes Enhanced periodontal health Improvement in clinical attachment level Reduction in bleeding on probing Reduction in probing depth |
| gptkbp:mandates |
Adjunct to scaling and root planing
|
| gptkbp:manufacturer |
gptkb:OraPharma,_Inc.
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:United_States Europe |
| gptkbp:offers |
Varies by provider
|
| gptkbp:packaging |
Single-use applicator
|
| gptkbp:patentStatus |
Patent protected
|
| gptkbp:regulatoryCompliance |
FDA_approved
|
| gptkbp:route |
Topical
|
| gptkbp:safetyFeatures |
Generally well tolerated
|
| gptkbp:sideEffect |
Nausea
Headache Taste disturbance |
| gptkbp:storage |
Room temperature
|
| gptkbp:triggerType |
Antimicrobial
|
| gptkbp:usedFor |
Periodontal disease
|